Relmada Therapeutics, Inc. (RLMD) Financials

RLMD Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 109.1 million 8.4 million
2023-06-30 122.0 million 10.7 million
2023-03-31 135.6 million 10.1 million
2022-12-31 152.9 million 12.5 million

RLMD Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -11.6 million 11.4 million
2023-06-30 -13.3 million 11.2 million
2023-03-31 -16.5 million 11.4 million
2022-12-31 -35.9 million 11.6 million

RLMD Net Income

No data available :(

RLMD Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 106.3 million - -
2023-06-30 118.5 million - -
2023-03-31 132.4 million - -
2022-12-31 148.3 million - -

RLMD Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 30.1 million
2023-06-30 30.1 million
2023-03-31 30.1 million
2022-12-31 29.6 million

RLMD Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 10.5 million 12.2 million -
2023-06-30 - 13.7 million 12.3 million -
2023-03-31 - 15.9 million 12.3 million -
2022-12-31 - 26.9 million 11.8 million -

RLMD Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - -
2023-06-30 - -
2023-03-31 - -
2022-12-31 - -

RLMD

Price: $3.68

52 week price:
2.28
7.22

Earnings Per Share: -3.28 USD

P/E Ratio: -1.51

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 144200

Market Capitalization: 146.6 million

Links: